PolyPeptide Group (PPGN) Stock Overview
Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PPGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Biotech longerterm bet
PolyPeptide Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 39.35 |
| 52 Week High | CHF 41.70 |
| 52 Week Low | CHF 19.62 |
| Beta | 1.03 |
| 1 Month Change | 2.61% |
| 3 Month Change | 59.96% |
| 1 Year Change | 98.14% |
| 3 Year Change | 103.89% |
| 5 Year Change | -53.87% |
| Change since IPO | -49.68% |
Recent News & Updates
Recent updates
PolyPeptide Group (SWX:PPGN) Stock Could Be 8.9% Overvalued After Return To Profit
PolyPeptide Group (SWX:PPGN) has attracted fresh attention after swinging from a net loss to a net profit in its latest quarter, a shift that coincides with supportive analyst sentiment. See our latest analysis for PolyPeptide Group. The recent swing to profit appears to have coincided with a sharp improvement in sentiment, with PolyPeptide Group’s share price at CHF39.35 delivering a 59.96% 90 day share price return and a 98.14% 1 year total shareholder return, even though the 5 year total...
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
Catalysts About PolyPeptide Group PolyPeptide Group is a contract development and manufacturing partner focused on therapeutic peptides across development and commercial scales. What are the underlying business or industry changes driving this perspective?At CHF28.15, Is It Time To Put PolyPeptide Group AG (VTX:PPGN) On Your Watch List?
While PolyPeptide Group AG ( VTX:PPGN ) might not have the largest market cap around , it saw a significant share price...Market Cool On PolyPeptide Group AG's (VTX:PPGN) Revenues
PolyPeptide Group AG's ( VTX:PPGN ) price-to-sales (or "P/S") ratio of 2.4x might make it look like a buy right now...PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29
SWX:PPGN 1 Year Share Price vs Fair Value Explore PolyPeptide Group's Fair Values from the Community and select yours...PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story
Despite an already strong run, PolyPeptide Group AG ( VTX:PPGN ) shares have been powering on, with a gain of 28% in...Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...PolyPeptide Group AG (VTX:PPGN) Might Not Be As Mispriced As It Looks After Plunging 28%
To the annoyance of some shareholders, PolyPeptide Group AG ( VTX:PPGN ) shares are down a considerable 28% in the last...Why PolyPeptide Group AG (VTX:PPGN) Could Be Worth Watching
PolyPeptide Group AG ( VTX:PPGN ), is not the largest company out there, but it received a lot of attention from a...Many Still Looking Away From PolyPeptide Group AG (VTX:PPGN)
When close to half the companies operating in the Life Sciences industry in Switzerland have price-to-sales ratios (or...PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, PolyPeptide Group fair value estimate is CHF25.02 PolyPeptide...PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)
You may think that with a price-to-sales (or "P/S") ratio of 3.7x PolyPeptide Group AG ( VTX:PPGN ) is a stock worth...Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
PolyPeptide Group AG ( VTX:PPGN ) shareholders would be excited to see that the share price has had a great month...PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for PolyPeptide Group is CHF39.76 based on 2 Stage Free Cash Flow to Equity...PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a major selloff in PolyPeptide Group AG ( VTX:PPGN ) shares in the week since it released its yearly...Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Despite posting some strong earnings, the market for PolyPeptide Group AG's ( VTX:PPGN ) stock hasn't moved much. Our...Shareholder Returns
| PPGN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 16.2% | 0.8% | 0.5% |
| 1Y | 98.1% | -8.8% | 14.8% |
Return vs Industry: PPGN exceeded the Swiss Life Sciences industry which returned -10% over the past year.
Return vs Market: PPGN exceeded the Swiss Market which returned 13.1% over the past year.
Price Volatility
| PPGN volatility | |
|---|---|
| PPGN Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: PPGN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: PPGN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,440 | Juan Gonzalez | www.polypeptide.com |
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1.
PolyPeptide Group AG Fundamentals Summary
| PPGN fundamental statistics | |
|---|---|
| Market cap | CHF 1.23b |
| Earnings (TTM) | -CHF 19.56m |
| Revenue (TTM) | CHF 359.75m |
Is PPGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPGN income statement (TTM) | |
|---|---|
| Revenue | €389.33m |
| Cost of Revenue | €324.04m |
| Gross Profit | €65.29m |
| Other Expenses | €86.46m |
| Earnings | -€21.17m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 13, 2026
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 16.77% |
| Net Profit Margin | -5.44% |
| Debt/Equity Ratio | 35.3% |
How did PPGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/19 05:18 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyPeptide Group AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Andrew Wood | BofA Global Research |